Axial Shortening in Myopic Children after Repeated Low-Level Red-Light Therapy: Post Hoc Analysis of a Randomized Trial.

Abstract

Axial length (AL) elongation in myopia is considered irreversible. We aimed to systemically report unexpected AL shortening observed in a randomized clinical trial (RCT) after repeated low-level red-light (RLRL) therapy. This is a post hoc analysis of a multicenter, single-masked RCT. Two hundred sixty-four myopic children aged 8-13years allocated to RLRL treatment (intervention group) or a single vision spectacle (SVS, control group) were included. AL was measured using an IOL-master 500 at baseline, 1-, 3-, 6-, and 12-month follow-up visits. AL shortening was defined as AL reduction from baseline to follow-up visits at three cutoffs: > 0.05mm, > 0.10mm, and > 0.20mm. Frequency of AL shortening at different cutoffs was calculated. Analysis was done with intent to treat (ITT). At 12-months follow up, frequency of AL shortening > 0.05mm was 26/119 (21.85%) and 2/145 (1.38%) for the RLRL group versus the control group, respectively. The frequency was 18/119 (15.13%) versus 0/145 (0%) for AL shortening > 0.10mm, and 7/119 (5.88%) versus 0/145 (0%), for AL shortening > 0.20mm, respectively (p < 0.001). Mean AL shortening after 12months (SD) was -0.156 (0.086) mm in the RLRL group and -0.06mm in the control group. Age was significantly associated with AL shortening in the multivariable analysis. For the RLRL group that exhibited AL shortening (n = 56), choroidal thickness (ChT) thickening (0.056mm) could only explain 28.3% of AL shortening (-0.20mm). Nearly a quarter of children had > 0.05mm AL shortening following 12months of RLRL therapy, whereas AL shortening rarely occurred among controls. ClinicalTrials.gov (NCT04073238).